Lives could be saved from tropical disease with new rapid test

A new test diagnoses patients with melioidosis within hours, rather than days, meaning they can receive the correct antibiotics faster

2024-03-14

(Press-News.org) Globally, more than half of patients die after infection with the neglected tropical disease, melioidosis, often before they are diagnosed1. A new rapid test could save lives by diagnosing patients in hours, rather than several days taken by current bacterial culture methods, meaning they receive the correct antibiotics faster.

The test uses CRISPR to detect a genetic target that is specific to Burkholderia pseudomallei, the bacterium that causes melioidosis, with 93 per cent sensitivity. It was developed by researchers at the Mahidol-Oxford Tropical Medicine Research Unit (MORU), Chiang Mai University, Vidyasirimedhi Institute of Science and Technology (VISTEC) in Thailand, and the Wellcome Sanger Institute in the UK.

The results, published today (14 March) in Lancet Microbe, mean more lives could be saved from melioidosis, with a rapid, easy-to-use diagnostic test that could be rolled out globally.

Melioidosis is a neglected tropical disease that is estimated to affect 165,000 people worldwide each year, of whom 89,000 die from the disease1. It is caused by the bacterium, Burkholderia pseudomallei, which lives in soil and water in tropical and subtropical regions, and enters human bodies via inoculation through skin abrasions, ingestion or inhalation.

It is difficult to diagnose melioidosis as symptoms vary from localised abscess or pneumonia to acute septicaemia, or may present as a chronic infection. As a result of this, and the locations of isolated communities in rural areas that it mostly affects, the disease remains hugely underreported.

Currently, melioidosis is diagnosed in patients after bacterial samples are cultured, which takes three to four days. In Thailand, approximately 40 per cent of patients with melioidosis die2, many of whom die within the first one to two days following admission to hospital, while waiting for a diagnosis.

There is no licensed vaccine for melioidosis, but patients can be effectively treated with intravenous antibiotics – ceftazidime or carbapenem – during the first intensive phase of treatment. However, current practices often involve initially treating patients with a range of unnecessary antibiotics to target the various symptoms the disease produces, which can waste time and resources.

In a new study, the team set out to develop a new rapid test to reduce the time taken to correctly diagnose and treat patients with melioidosis.

The researchers identified a genetic target specific to B. pseudomallei by analysing over 3,000 B. pseudomallei genomes, most of which were sequenced at the Sanger Institute. They searched for conserved regions of the genome and screened the targets against other pathogens and human host genomes, to ensure their chosen target was specific to B. pseudomallei.

Their test, called CRISPR-BP34, involves rupturing bacterial cells and using a recombinase polymerase amplification reaction to amplify the bacterial target DNA for increased sensitivity. Additionally, a CRISPR reaction is used to provide specificity, and a simple lateral flow ‘dipstick’ read-out is employed to confirm cases of melioidosis.

To assess the efficacy of the test, the team collected clinical samples from 114 patients with melioidosis and 216 patients without the disease at Sunpasitthiprasong Hospital, a hospital in northeast Thailand where melioidosis is endemic. The CRISPR-BP34 test was then applied to these samples.

The new test showed enhanced sensitivity at 93 per cent, compared to 66.7 per cent in bacterial culture methods. It also delivered results in less than four hours for urine, pus, and sputum samples, and within one day for blood samples. This is a significant improvement over the current bacterial culture diagnostic method, which typically takes three to four days.

This new rapid diagnostic test will enable health professionals to prescribe the correct antibiotics faster, meaning fewer patients will die while waiting for a diagnosis. While saving precious time, the new test will also save resources and money, with fewer unnecessary antibiotics prescribed and less time for patients in hospital.

In next steps for the team, they are currently designing randomised clinical trials to show the effectiveness of these tests in hospital settings. Plus, members of the team will begin investigating the role of human genetics in susceptibility and immune response to melioidosis infection.

Dr Claire Chewapreecha, co-lead author at the Mahidol-Oxford Tropical Medicine Research Unit (MORU), Thailand, and Wellcome Sanger Institute International Fellow, said: "Working in rural Thailand has many limitations. But we have shown that limitations breed innovation, and what succeeds here can succeed anywhere. I am so proud of the team behind this new, robust rapid diagnostic test for melioidosis, and hope that it can potentially be used anywhere in the world to get the right treatments to patients faster, ultimately saving lives."

Dr Somsakul Wongpalee, co-lead author at Chiang Mai University, Thailand, said: "We carefully designed the rapid diagnostic test based on CRISPR-BP34, with a robust algorithm, and tested its performance in vitro. We are thrilled that the CRISPR-BP34 test demonstrates outstanding diagnostic efficacy when tested on clinical samples, showcasing its potential to significantly impact patient outcomes and potentially save lives in the near future."

Professor Nick Thomson, senior author and Head of Parasites and Microbes at the Wellcome Sanger Institute, said: “This research is a testament to international collaboration and how the application of genomics at scale leads to clinical intervention. Using a genetic target mined from a bank of thousands of bacterial genomes, the team was able to produce an incredibly sensitive test that is specific to the bacterium behind melioidosis. I look forward to seeing the clinical impacts of this research.”

Professor Nick Day, senior author and Director of the Mahidol-Oxford Tropical Medicine Research Unit (MORU), Thailand, and the Wellcome Trust Thailand Asia and Africa Programme, said: “Melioidosis has been neglected despite its high mortality rate and high incidence in many parts of Asia. Early diagnosis is essential so that the specific treatment required can be started as soon as possible. The new rapid diagnostic tool developed through this collaboration has the potential to be a game-changer.”

ENDS

Notes to Editors:

1. https://pubmed.ncbi.nlm.nih.gov/27571754/

2. https://pubmed.ncbi.nlm.nih.gov/32083145/

The research team would like to thank Sunpasitthiprasong Hospital in Ubon, where their clinical site was based, and VISTEC, who provided technical support. Without these collaborations, the project would not have been possible.

Publication:

S. Wongpalee, C Chewapreecha, et al. (2024) Benchmarking CRISPR-BP34 for point-of-care melioidosis detection in low-income and middle-income countries: a molecular diagnostics study. Lancet Microbe. DOI: 10.1016/S2666-5247(23)00378-6

On publication, the URL for the article will be: https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(23)00378-6/fulltext

Funding:
This research was funded by Wellcome and Chiang Mai University, Thailand.

Selected websites:

Chiang Mai University
Chiang Mai University (CMU) is a leading higher education institution located in the cultural city of Chiang Mai, Thailand. Established in 1964, CMU has evolved into a prestigious research university renowned for its academic excellence, innovative programs, and commitment to community engagement. Committed to fostering global perspectives and sustainable development, CMU collaborates with international partners and conducts groundbreaking research to address societal challenges and promote knowledge advancement. As a beacon of learning and innovation, Chiang Mai University continues to empower future generations to thrive in a rapidly changing world. Find out more at https://cmu.ac.th/en/ [cmu.ac.th]

Mahidol-Oxford Tropical Medicine Research Unit (MORU)
The Mahidol Oxford Tropical Medicine Research Unit (MORU), www.tropmedres.ac [tropmedres.ac], @MORUBKK, is a Bangkok-centered research collaboration between Mahidol University [tm.mahidol.ac.th] (Thailand), the University of Oxford [ndm.ox.ac.uk] and Wellcome [wellcome.ac.uk] (UK). The MORU Tropical Health Network, which hosts the Thailand Wellcome Africa and Asia Programme, conducts targeted clinical and public health research that aims to discover and develop appropriate, practical, affordable interventions that measurably improve the health of people living in resource-limited parts of the world.

The Wellcome Sanger Institute
The Wellcome Sanger Institute is a world leader in genomics research. We apply and explore genomic technologies at scale to advance understanding of biology and improve health. Making discoveries not easily made elsewhere, our research delivers insights across health, disease, evolution and pathogen biology. We are open and collaborative; our data, results, tools, technologies and training are freely shared across the globe to advance science.

Funded by Wellcome, we have the freedom to think long-term and push the boundaries of genomics. We take on the challenges of applying our research to the real world, where we aim to bring benefit to people and society.

Find out more at www.sanger.ac.uk or follow us on Twitter, Instagram, Facebook, LinkedIn and on our Blog.

About Wellcome
Wellcome supports science to solve the urgent health challenges facing everyone. We support discovery research into life, health and wellbeing, and we’re taking on three worldwide health challenges: mental health, infectious disease and climate and health. https://wellcome.org/

END

ELSE PRESS RELEASES FROM THIS DATE:

Revolutionary chronic wound treatment could help millions

2024-03-14

Revolutionary chronic wound treatment could help millions A team of international scientists has developed an effective treatment for preventing infection in chronic wounds that does not involve antibiotics The treatment involves the plasma (electrical gas) activation of hydrogel dressings to produce a unique mix of different chemical oxidants that applied to the wound are effective in decontaminating and aiding healing in chronic wounds The new method is a significant advance that could revolutionise the treatment of diabetic foot ulcers and internal wounds More than 540 million people ...

First-of-its-kind super minigene to boost spinal muscular atrophy research

2024-03-13

AMES, Iowa – Ravindra Singh has spent years studying a gene that when missing or mutated causes spinal muscular atrophy (SMA), a deadly disease that’s among the most common genetic disorders in children. His team’s latest work will make the search for treatments even more effective in the years to come. Singh, a professor of biomedical science at Iowa State University, led an eight-year project to create a truncated version of the Survival Motor Neuron 2 (SMN2) gene to facilitate quicker, cheaper and less fragmented research. Nucleic Acids Research, a peer-reviewed ...

NYU Tandon study exposes failings of measures to prevent illegal content generation by text-to-image AI models

2024-03-13

Researchers at NYU Tandon School of Engineering have revealed critical shortcomings in recently proposed methods aimed at making powerful text-to-image generative AI systems safer for public use. In a paper that will be presented at the Twelfth International Conference on Learning Representations (ICLR), taking place in Vienna on May 7 - 11, 2024, the research team demonstrates how techniques that claim to "erase" the ability of models like Stable Diffusion to generate explicit, copyrighted, or otherwise unsafe ...

New analysis shows tirzepatide consistently reduces bodyweight regardless of body mass index (BMI) before treatment

2024-03-13

*Note – this is an early press release from the European Congress on Obesity in Venice, Italy 12-15 May. Please credit the congress when using this research* Tirzepatide, a medication authorised to treat obesity and/or type 2 diabetes, consistently reduces bodyweight regardless of the patient’s body mass index (BMI before treatment), from the range of overweight to class III obesity. The study, to be presented at this year’s European Congress on Obesity (Venice, Italy, 12-15 May) is by Prof Carel Le Roux, University ...

Tirzepatide reduces body weight and waist circumference in people living with overweight or obesity regardless of duration of their condition

2024-03-13

*Note – this is an early press release from the European Congress on Obesity in Venice, Italy 12-15 May. Please credit the congress when using this research* New research to be presented at this year’s European Congress on Obesity (Venice, Italy, May 12-15) shows that the obesity medication tirzepatide consistently reduces bodyweight and waist circumference regardless of the length of time the person has been living with overweight or obesity. The study is by Dr Giovanna Muscogiuri, University of Naples Federico II, Naples, Italy, and colleagues. Tirzepatide (Mounjaro®) was approved by the US Food and ...

Scientists use novel technique to create new energy-efficient microelectronic device

2024-03-13

Breakthrough could help lead to the development of new low-power semiconductors or quantum devices. As the integrated circuits that power our electronic devices get more powerful, they are also getting smaller. This trend of microelectronics has only accelerated in recent years as scientists try to fit increasingly more semiconducting components on a chip. Microelectronics face a key challenge because of their small size. To avoid overheating, microelectronics need to consume only a fraction of the electricity of conventional electronics while still operating at peak performance. Researchers at the U.S. Department of Energy’s (DOE) Argonne National Laboratory ...

Jay Sexton receives 2024 SEC Faculty Achievement Award

2024-03-13

COLUMBIA, Mo. — In fourth grade, Jay Sexton first encountered one of James McPherson’s most influential works, “Battle Cry of Freedom: The Civil War Era.” That experience would ignite a lifelong passion for studying history and establish an ongoing legacy as a preeminent scholar in the study of the American story. As director of the Kinder Institute on Constitutional Democracy at the University of Missouri — a world-renowned academic center devoted to the study of the American founding, including constitutional ...

Canada Research Chair awarded to finance professor at the Rotman School of Management

2024-03-13

Toronto – A leading academic expert in household finance, Claire Célérier, who is an associate professor of finance at the University of Toronto’s Rotman School of Management, has been named by the Government of Canada as the Canada Research Chair in Household Finance. Prof. Célérier’s research explores how finance can benefit households, investigating the role of innovation and the impact on diversity and inclusion. She addresses these questions taking different ...

Water droplet spun by sound screens for colon cancer

2024-03-13

DURHAM, N.C. – Mechanical engineers at Duke University have devised a new type of diagnostic platform that uses sound waves to spin an individual drop of water up to 6,000 revolutions per minute. These speeds separate tiny biological particles within samples to enable new diagnostics based on exosomes. A very light disc placed on top of the spinning drop features etched channels that are equipped with star-shaped nanoparticles tailored to enable the label-free detection of specific disease-relevant bioparticles called exosomes. The technique ...

Study: Default testing for COVID-19 in K-12 schools more effective than voluntary testing

2024-03-13

CHAMPAIGN, Ill. — A new paper co-written by a team of University of Illinois Urbana-Champaign business professors found that default testing of K-12 students for COVID-19 during the pandemic could have saved up to one out of every five school days lost to the coronavirus during the fall 2021 semester. Schools adopting an “opt-out model” – in which students were regularly tested for COVID-19 unless they proactively declined or “opted out” of testing – experienced a 30% lower positivity rate than schools ...

LAST 30 PRESS RELEASES:

Global cervical cancer vaccine roll-out shows it to be very effective in reducing cervical cancer and other HPV-related disease, but huge variations between countries in coverage

Negativity about vaccines surged on Twitter after COVID-19 jabs become available

Global measles cases almost double in a year

Lower dose of mpox vaccine is safe and generates six-week antibody response equivalent to standard regimen

Personalised “cocktails” of antibiotics, probiotics and prebiotics hold great promise in treating a common form of irritable bowel syndrome, pilot study finds